These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 27197965)

  • 1. Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.
    Chen H; Liu X; Brendler CB; Ankerst DP; Leach RJ; Goodman PJ; Lucia MS; Tangen CM; Wang L; Hsu FC; Sun J; Kader AK; Isaacs WB; Helfand BT; Zheng SL; Thompson IM; Platz EA; Xu J
    Prostate; 2016 Sep; 76(12):1120-9. PubMed ID: 27197965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.
    Na R; Labbate C; Yu H; Shi Z; Fantus RJ; Wang CH; Andriole GL; Isaacs WB; Zheng SL; Helfand BT; Xu J
    JAMA Netw Open; 2019 Dec; 2(12):e1918145. PubMed ID: 31880795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.
    Shi Z; Platz EA; Wei J; Na R; Fantus RJ; Wang CH; Eggener SE; Hulick PJ; Duggan D; Zheng SL; Cooney KA; Isaacs WB; Helfand BT; Xu J
    Eur Urol; 2021 Mar; 79(3):419-426. PubMed ID: 33257031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.
    Na R; Ye D; Qi J; Liu F; Lin X; Helfand BT; Brendler CB; Conran C; Gong J; Wu Y; Gao X; Chen Y; Zheng SL; Mo Z; Ding Q; Sun Y; Xu J
    Asian J Androl; 2016; 18(4):525-9. PubMed ID: 27140652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of genetic risk score with family history for estimating prostate cancer risk.
    Helfand BT
    Asian J Androl; 2016; 18(4):515-9. PubMed ID: 27004541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical validity and utility of genetic risk scores in prostate cancer.
    Helfand BT; Kearns J; Conran C; Xu J
    Asian J Androl; 2016; 18(4):509-14. PubMed ID: 27297129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
    Kader AK; Sun J; Reck BH; Newcombe PJ; Kim ST; Hsu FC; D'Agostino RB; Tao S; Zhang Z; Turner AR; Platek GT; Spraggs CF; Whittaker JC; Lane BR; Isaacs WB; Meyers DA; Bleecker ER; Torti FM; Trent JM; McConnell JD; Zheng SL; Condreay LD; Rittmaster RS; Xu J
    Eur Urol; 2012 Dec; 62(6):953-61. PubMed ID: 22652152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
    Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
    Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exome-based genome-wide association study and risk assessment using genetic risk score to prostate cancer in the Korean population.
    Oh JJ; Lee SJ; Hwang JY; Kim D; Lee SE; Hong SK; Ho JN; Yoon S; Sung J; Kim WJ; Byun SS
    Oncotarget; 2017 Jul; 8(27):43934-43943. PubMed ID: 28380453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
    Sandahl M; Pedersen BG; Ulhøi BP; Borre M; Sørensen KD
    BJU Int; 2021 Dec; 128(6):702-712. PubMed ID: 33964113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between family history of prostate cancer and positive biopsies in a Brazilian screening program.
    Muller RL; Faria EF; Carvalhal GF; Reis RB; Mauad EC; Carvalho AL; Freedland SJ
    World J Urol; 2013 Oct; 31(5):1273-8. PubMed ID: 22820620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies.
    Xu J; Resurreccion WK; Shi Z; Wei J; Wang CH; Zheng SL; Hulick PJ; Ross AE; Pavlovich CP; Helfand BT; Isaacs WB
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):422-430. PubMed ID: 35347252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
    Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
    Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).
    Randazzo M; Müller A; Carlsson S; Eberli D; Huber A; Grobholz R; Manka L; Mortezavi A; Sulser T; Recker F; Kwiatkowski M
    BJU Int; 2016 Apr; 117(4):576-83. PubMed ID: 26332304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.
    Conran CA; Na R; Chen H; Jiang D; Lin X; Zheng SL; Brendler CB; Xu J
    Asian J Androl; 2016; 18(4):520-4. PubMed ID: 27080480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts.
    Seibert TM; Fan CC; Wang Y; Zuber V; Karunamuni R; Parsons JK; Eeles RA; Easton DF; Kote-Jarai Z; Al Olama AA; Garcia SB; Muir K; Grönberg H; Wiklund F; Aly M; Schleutker J; Sipeky C; Tammela TL; Nordestgaard BG; Nielsen SF; Weischer M; Bisbjerg R; Røder MA; Iversen P; Key TJ; Travis RC; Neal DE; Donovan JL; Hamdy FC; Pharoah P; Pashayan N; Khaw KT; Maier C; Vogel W; Luedeke M; Herkommer K; Kibel AS; Cybulski C; Wokolorczyk D; Kluzniak W; Cannon-Albright L; Brenner H; Cuk K; Saum KU; Park JY; Sellers TA; Slavov C; Kaneva R; Mitev V; Batra J; Clements JA; Spurdle A; Teixeira MR; Paulo P; Maia S; Pandha H; Michael A; Kierzek A; Karow DS; Mills IG; Andreassen OA; Dale AM;
    BMJ; 2018 Jan; 360():j5757. PubMed ID: 29321194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate genetic score (PGS-33) is independently associated with risk of prostate cancer in the PLCO trial.
    Liss MA; Xu J; Chen H; Kader AK
    Prostate; 2015 Sep; 75(12):1322-8. PubMed ID: 25982801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.
    Winchester DA; Till C; Goodman PJ; Tangen CM; Santella RM; Johnson-Pais TL; Leach RJ; Xu J; Zheng SL; Thompson IM; Lucia MS; Lippman SM; Parnes HL; Isaacs WB; De Marzo AM; Drake CG; Platz EA
    Prostate; 2017 Jun; 77(8):908-919. PubMed ID: 28317149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of prostate cancer from prostate biopsy in Chinese men using a genetic score derived from 24 prostate cancer risk-associated SNPs.
    Jiang H; Liu F; Wang Z; Na R; Zhang L; Wu Y; Zheng J; Lin X; Jiang D; Sun J; Zheng SL; Ding Q; Xu J
    Prostate; 2013 Nov; 73(15):1651-9. PubMed ID: 23868750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.
    Chen H; Na R; Packiam VT; Conran CA; Jiang D; Tao S; Yu H; Lin X; Meng W; Zheng SL; Brendler CB; Helfand BT; Xu J
    Prostate; 2017 Aug; 77(11):1179-1186. PubMed ID: 28670847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.